Study Group: Coreg Prescribers: Cardiologists (US)
Council Members in this Study Group: 93
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Daniel Fisher
Cardiologist
NEW YORK UNIVERSITY (INC)
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....
- Howard Weintraub
Clinical Director
NEW YORK UNIVERSITY (INC)Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub...
- Joshua Feuer
Owner
JOSHUA M FEUERJoshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and...
Bernard ChaitmanProfessor and Director
SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINEBernard Chaitman, MD, is Professor of Internal Medicine and Director of Cardiovascular Research at the St. Louis University School of Medicine in Missouri. He is also the Director of the Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal...
- Dale Mueller
Vice-Chairman of Cardiovascular Medicine
OSF SAINT FRANCIS MEDICAL CTRDale Mueller, MD, is a Cardiovascular and Thoracic Surgeon at Heartcare Midwest and Vice-Chairman of the Department of Cardiovascular Medicine and Surgery at OSF Saint Francis Medical Center in Illinois. He has expertise in cardiac surgery including minimally-invasive...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
If it seems too good to be true...it probably is.
December 9, 2008
Analysis by: Joshua Feuer, Owner,Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.
-
December 8, 2008
Analysis by: Joshua Feuer, Owner,There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.
-
Another piece of good news for a very good drug
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level of BNP. This has not been as successful in patients without myocardial ischemia, but in those with ischemia the shortness of breath and associated chest discomfort has been helped in many. Including the most recent patient with a severe ischemic cardiomyopathy who has responded very very well with a significant increase in his functional capacity. Hopefully this news along with the safety from MERLIN and the A1C data and reduction in arrhythmias in that study will awaken docs to the benefits of Ranexa.
-
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
-
June 15, 2007
Analysis by: Howard Weintraub, Clinical Director,FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in the near and mid-term future. This does not bode well for Sanofi, who will not have to regroup and pray for success with son of Amiodarone.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Physician - Division Head